274 related articles for article (PubMed ID: 28857806)
1. Reversing Dabigatran Anticoagulation with Prothrombin Complex Concentrate versus Idarucizumab as Part of Multimodal Hemostatic Intervention in an Animal Model of Polytrauma.
Honickel M; Braunschweig T; Rossaint R; Stoppe C; Ten Cate H; Grottke O
Anesthesiology; 2017 Nov; 127(5):852-861. PubMed ID: 28857806
[TBL] [Abstract][Full Text] [Related]
2. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
[TBL] [Abstract][Full Text] [Related]
3. Reversing Rivaroxaban Anticoagulation as Part of a Multimodal Hemostatic Intervention in a Polytrauma Animal Model.
Rayatdoost F; Braunschweig T; Maron B; Schöchl H; Akman N; Rossaint R; Herzog E; Heitmeier S; Grottke O
Anesthesiology; 2021 Oct; 135(4):673-685. PubMed ID: 34370811
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of combined idarucizumab and prothrombin complex concentrate treatment for bleeding related to dabigatran in a lethal porcine model of double trauma.
Honickel M; Braunschweig T; Rossaint R; Schöchl H; Grottke O
Transfusion; 2019 Apr; 59(4):1376-1387. PubMed ID: 30586470
[TBL] [Abstract][Full Text] [Related]
5. Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model.
Honickel M; Maron B; van Ryn J; Braunschweig T; ten Cate H; Spronk HM; Rossaint R; Grottke O
Thromb Haemost; 2016 Jan; 115(2):271-84. PubMed ID: 26333775
[TBL] [Abstract][Full Text] [Related]
6. Prothrombin Complex Concentrate Is Effective in Treating the Anticoagulant Effects of Dabigatran in a Porcine Polytrauma Model.
Honickel M; Braunschweig T; van Ryn J; Ten Cate H; Spronk HM; Rossaint R; Grottke O
Anesthesiology; 2015 Dec; 123(6):1350-61. PubMed ID: 26414500
[TBL] [Abstract][Full Text] [Related]
7. Reversal of dabigatran by intraosseous or intravenous idarucizumab in a porcine polytrauma model.
Akman N; Braunschweig T; Honickel M; Schütt K; Schöchl H; Stoppe C; Rossaint R; Grottke O
Br J Anaesth; 2018 May; 120(5):978-987. PubMed ID: 29661415
[TBL] [Abstract][Full Text] [Related]
8. Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding.
Honickel M; Spronk HM; Rossaint R; Stoppe C; van Ryn J; Ten Cate H; Grottke O
Thromb Haemost; 2017 Jun; 117(7):1370-1378. PubMed ID: 28424818
[TBL] [Abstract][Full Text] [Related]
9. Hemostatic Therapy Using Tranexamic Acid and Coagulation Factor Concentrates in a Model of Traumatic Liver Injury.
Zentai C; van der Meijden PE; Braunschweig T; Hueck N; Honickel M; Spronk HM; Rossaint R; Grottke O
Anesth Analg; 2016 Jul; 123(1):38-48. PubMed ID: 27192476
[TBL] [Abstract][Full Text] [Related]
10. Reversing the anticoagulation effects of dabigatran.
Dager WE; Banares L
Hosp Pract (1995); 2017 Apr; 45(2):29-38. PubMed ID: 28335637
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
Glund S; Stangier J; Schmohl M; Gansser D; Norris S; van Ryn J; Lang B; Ramael S; Moschetti V; Gruenenfelder F; Reilly P; Kreuzer J
Lancet; 2015 Aug; 386(9994):680-90. PubMed ID: 26088268
[TBL] [Abstract][Full Text] [Related]
12. Idarucizumab, a Specific Dabigatran Reversal Agent, Reduces Blood Loss in a Porcine Model of Trauma With Dabigatran Anticoagulation.
Grottke O; Honickel M; van Ryn J; ten Cate H; Rossaint R; Spronk HM
J Am Coll Cardiol; 2015 Sep; 66(13):1518-9. PubMed ID: 26403349
[No Abstract] [Full Text] [Related]
13. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
Thibault N; Morrill AM; Willett KC
Am J Ther; 2018; 25(3):e333-e338. PubMed ID: 27175894
[TBL] [Abstract][Full Text] [Related]
14. Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study.
Pollack CV; Bernstein R; Dubiel R; Reilly P; Gruenenfelder F; Huisman MV; Kam CW; Kleine E; Levy JH; Sellke FW; Steiner T; Ustyugova A; Weitz JI
J Med Econ; 2017 May; 20(5):435-442. PubMed ID: 27981865
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation.
Grottke O; Aisenberg J; Bernstein R; Goldstein P; Huisman MV; Jamieson DG; Levy JH; Pollack CV; Spyropoulos AC; Steiner T; Del Zoppo GJ; Eikelboom J
Crit Care; 2016 Apr; 20(1):115. PubMed ID: 27125504
[TBL] [Abstract][Full Text] [Related]
16. Management of dabigatran after overdosage: two case reports and suggestions for monitoring.
Billoir P; Girault C; Barbay V; Boyer D; Grangé S; Fresel M; Chrétien MH; Le Cam Duchez V
Blood Coagul Fibrinolysis; 2018 Nov; 29(7):653-655. PubMed ID: 30045050
[TBL] [Abstract][Full Text] [Related]
17. Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants.
Gómez-Outes A; Alcubilla P; Calvo-Rojas G; Terleira-Fernández AI; Suárez-Gea ML; Lecumberri R; Vargas-Castrillón E
J Am Coll Cardiol; 2021 Jun; 77(24):2987-3001. PubMed ID: 34140101
[TBL] [Abstract][Full Text] [Related]
18. Incomplete dabigatran reversal with idarucizumab.
Steele AP; Lee JA; Dager WE
Clin Toxicol (Phila); 2018 Mar; 56(3):216-218. PubMed ID: 28704111
[TBL] [Abstract][Full Text] [Related]
19. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
[TBL] [Abstract][Full Text] [Related]
20. Idarucizumab: First Global Approval.
Burness CB
Drugs; 2015 Dec; 75(18):2155-61. PubMed ID: 26578027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
